Minerva Neurosciences, Inc. Operating Lease Cost
Minerva Neurosciences, Inc. (NERV) reported Operating Lease Cost of $59.97 thousand for the 3-month period ending 2022-03-31, per its 10-Q filed 2022-05-04.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2022-05-04
- Minerva Neurosciences, Inc. operating lease, cost for the quarter ending 2022-03-31 was $59.97K.
- Minerva Neurosciences, Inc. operating lease, cost for the quarter ending 2021-12-31 was $59.97K.
- Minerva Neurosciences, Inc. operating lease, cost for fiscal 2021 was $99.95K.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 6 month | Operating Lease, Cost 9 month | Operating Lease, Cost 12 month |
|---|---|---|---|---|
| 2022-03-31 | $59.97K 10-Q · filed 2022-05-04 | $119.94K derived: sum of 2 quarters · filed 2022-05-04 | ||
| 2021-12-31 | $59.97K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $99.95K 10-K · filed 2022-03-01 | ||
| 2021-09-30 | $39.98K 10-Q · filed 2021-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |